hs683 glioblastoma cells  (CLS Cell Lines Service GmbH)


Bioz Verified Symbol CLS Cell Lines Service GmbH is a verified supplier
Bioz Manufacturer Symbol CLS Cell Lines Service GmbH manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91

    Structured Review

    CLS Cell Lines Service GmbH hs683 glioblastoma cells
    Hypermethylation and histone modifications account for transcriptional downregulation of DIRAS-1 and DIRAS-2. ( A ) Increase in DIRAS-1 and DIRAS-2 mRNA expression in U251MG and <t>Hs683</t> cells after treatment with 5-azacytidine, ( B ) after treatment with trichostatin A (TSA), and ( C ) after combinational treatment with 5-azacytidine and trichostatin A. ( D ) Increase in DIRAS-1 and DIRAS-2 promoter DNA bound to acetylated H3, indicating DIRAS-1 and DIRAS-2 promoter euchromatinization after TSA treatment in U251MG and Hs683 cells (n.s.: not significant, * p ≤ 0.05, ** p ≤ 0.002, *** p ≤ 0.001). Original figure in .
    Hs683 Glioblastoma Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hs683 glioblastoma cells/product/CLS Cell Lines Service GmbH
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hs683 glioblastoma cells - by Bioz Stars, 2024-04
    91/100 stars

    Images

    1) Product Images from "Frequent Epigenetic Inactivation of DIRAS-1 and DIRAS-2 Contributes to Chemo-Resistance in Gliomas"

    Article Title: Frequent Epigenetic Inactivation of DIRAS-1 and DIRAS-2 Contributes to Chemo-Resistance in Gliomas

    Journal: Cancers

    doi: 10.3390/cancers13205113

    Hypermethylation and histone modifications account for transcriptional downregulation of DIRAS-1 and DIRAS-2. ( A ) Increase in DIRAS-1 and DIRAS-2 mRNA expression in U251MG and Hs683 cells after treatment with 5-azacytidine, ( B ) after treatment with trichostatin A (TSA), and ( C ) after combinational treatment with 5-azacytidine and trichostatin A. ( D ) Increase in DIRAS-1 and DIRAS-2 promoter DNA bound to acetylated H3, indicating DIRAS-1 and DIRAS-2 promoter euchromatinization after TSA treatment in U251MG and Hs683 cells (n.s.: not significant, * p ≤ 0.05, ** p ≤ 0.002, *** p ≤ 0.001). Original figure in .
    Figure Legend Snippet: Hypermethylation and histone modifications account for transcriptional downregulation of DIRAS-1 and DIRAS-2. ( A ) Increase in DIRAS-1 and DIRAS-2 mRNA expression in U251MG and Hs683 cells after treatment with 5-azacytidine, ( B ) after treatment with trichostatin A (TSA), and ( C ) after combinational treatment with 5-azacytidine and trichostatin A. ( D ) Increase in DIRAS-1 and DIRAS-2 promoter DNA bound to acetylated H3, indicating DIRAS-1 and DIRAS-2 promoter euchromatinization after TSA treatment in U251MG and Hs683 cells (n.s.: not significant, * p ≤ 0.05, ** p ≤ 0.002, *** p ≤ 0.001). Original figure in .

    Techniques Used: Expressing

    Functional analyses of the role of DIRAS-1 and DIRAS-2 in human gliomas. ( A ) Western blot analysis showing DIRAS-1 and DIRAS-2 overexpression in U251MG and Hs683 cells. Detailed information about Western Blots can be found in the . ( B ) Cell proliferation after overexpression of DIRAS-1 or DIRAS-2 and ( C ) chemosensitivity to lomustin after overexpression of DIRAS-1 or DIRAS-2 in U251MG and Hs683 cells (n.s.: not significant, * p ≤ 0.05, ** p ≤ 0.002). Original figure in .
    Figure Legend Snippet: Functional analyses of the role of DIRAS-1 and DIRAS-2 in human gliomas. ( A ) Western blot analysis showing DIRAS-1 and DIRAS-2 overexpression in U251MG and Hs683 cells. Detailed information about Western Blots can be found in the . ( B ) Cell proliferation after overexpression of DIRAS-1 or DIRAS-2 and ( C ) chemosensitivity to lomustin after overexpression of DIRAS-1 or DIRAS-2 in U251MG and Hs683 cells (n.s.: not significant, * p ≤ 0.05, ** p ≤ 0.002). Original figure in .

    Techniques Used: Functional Assay, Western Blot, Over Expression

    hs683 glioblastoma cells  (CLS Cell Lines Service GmbH)


    Bioz Verified Symbol CLS Cell Lines Service GmbH is a verified supplier
    Bioz Manufacturer Symbol CLS Cell Lines Service GmbH manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 91

    Structured Review

    CLS Cell Lines Service GmbH hs683 glioblastoma cells
    Hypermethylation and histone modifications account for transcriptional downregulation of DIRAS-1 and DIRAS-2. ( A ) Increase in DIRAS-1 and DIRAS-2 mRNA expression in U251MG and <t>Hs683</t> cells after treatment with 5-azacytidine, ( B ) after treatment with trichostatin A (TSA), and ( C ) after combinational treatment with 5-azacytidine and trichostatin A. ( D ) Increase in DIRAS-1 and DIRAS-2 promoter DNA bound to acetylated H3, indicating DIRAS-1 and DIRAS-2 promoter euchromatinization after TSA treatment in U251MG and Hs683 cells (n.s.: not significant, * p ≤ 0.05, ** p ≤ 0.002, *** p ≤ 0.001). Original figure in .
    Hs683 Glioblastoma Cells, supplied by CLS Cell Lines Service GmbH, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/hs683 glioblastoma cells/product/CLS Cell Lines Service GmbH
    Average 91 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    hs683 glioblastoma cells - by Bioz Stars, 2024-04
    91/100 stars

    Images

    1) Product Images from "Frequent Epigenetic Inactivation of DIRAS-1 and DIRAS-2 Contributes to Chemo-Resistance in Gliomas"

    Article Title: Frequent Epigenetic Inactivation of DIRAS-1 and DIRAS-2 Contributes to Chemo-Resistance in Gliomas

    Journal: Cancers

    doi: 10.3390/cancers13205113

    Hypermethylation and histone modifications account for transcriptional downregulation of DIRAS-1 and DIRAS-2. ( A ) Increase in DIRAS-1 and DIRAS-2 mRNA expression in U251MG and Hs683 cells after treatment with 5-azacytidine, ( B ) after treatment with trichostatin A (TSA), and ( C ) after combinational treatment with 5-azacytidine and trichostatin A. ( D ) Increase in DIRAS-1 and DIRAS-2 promoter DNA bound to acetylated H3, indicating DIRAS-1 and DIRAS-2 promoter euchromatinization after TSA treatment in U251MG and Hs683 cells (n.s.: not significant, * p ≤ 0.05, ** p ≤ 0.002, *** p ≤ 0.001). Original figure in .
    Figure Legend Snippet: Hypermethylation and histone modifications account for transcriptional downregulation of DIRAS-1 and DIRAS-2. ( A ) Increase in DIRAS-1 and DIRAS-2 mRNA expression in U251MG and Hs683 cells after treatment with 5-azacytidine, ( B ) after treatment with trichostatin A (TSA), and ( C ) after combinational treatment with 5-azacytidine and trichostatin A. ( D ) Increase in DIRAS-1 and DIRAS-2 promoter DNA bound to acetylated H3, indicating DIRAS-1 and DIRAS-2 promoter euchromatinization after TSA treatment in U251MG and Hs683 cells (n.s.: not significant, * p ≤ 0.05, ** p ≤ 0.002, *** p ≤ 0.001). Original figure in .

    Techniques Used: Expressing

    Functional analyses of the role of DIRAS-1 and DIRAS-2 in human gliomas. ( A ) Western blot analysis showing DIRAS-1 and DIRAS-2 overexpression in U251MG and Hs683 cells. Detailed information about Western Blots can be found in the . ( B ) Cell proliferation after overexpression of DIRAS-1 or DIRAS-2 and ( C ) chemosensitivity to lomustin after overexpression of DIRAS-1 or DIRAS-2 in U251MG and Hs683 cells (n.s.: not significant, * p ≤ 0.05, ** p ≤ 0.002). Original figure in .
    Figure Legend Snippet: Functional analyses of the role of DIRAS-1 and DIRAS-2 in human gliomas. ( A ) Western blot analysis showing DIRAS-1 and DIRAS-2 overexpression in U251MG and Hs683 cells. Detailed information about Western Blots can be found in the . ( B ) Cell proliferation after overexpression of DIRAS-1 or DIRAS-2 and ( C ) chemosensitivity to lomustin after overexpression of DIRAS-1 or DIRAS-2 in U251MG and Hs683 cells (n.s.: not significant, * p ≤ 0.05, ** p ≤ 0.002). Original figure in .

    Techniques Used: Functional Assay, Western Blot, Over Expression

    Similar Products

    No Results Found